Daiwa Securities Group Inc. Boosts Stake in DexCom, Inc. (NASDAQ:DXCM)

Daiwa Securities Group Inc. lifted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 4.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 56,725 shares of the medical device company’s stock after buying an additional 2,339 shares during the period. Daiwa Securities Group Inc.’s holdings in DexCom were worth $7,039,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Centaurus Financial Inc. increased its position in DexCom by 5.5% during the first quarter. Centaurus Financial Inc. now owns 1,236 shares of the medical device company’s stock worth $632,000 after purchasing an additional 64 shares during the last quarter. Stableford Capital II LLC increased its position in DexCom by 2.1% during the fourth quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock worth $563,000 after purchasing an additional 88 shares during the last quarter. Fortis Capital Advisors LLC increased its position in shares of DexCom by 5.5% during the second quarter. Fortis Capital Advisors LLC now owns 1,744 shares of the medical device company’s stock valued at $224,000 after acquiring an additional 91 shares during the last quarter. Ascent Group LLC increased its position in shares of DexCom by 2.1% during the third quarter. Ascent Group LLC now owns 4,778 shares of the medical device company’s stock valued at $577,000 after acquiring an additional 98 shares during the last quarter. Finally, Jaffetilchin Investment Partners LLC increased its position in shares of DexCom by 7.7% during the first quarter. Jaffetilchin Investment Partners LLC now owns 1,412 shares of the medical device company’s stock valued at $440,000 after acquiring an additional 101 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on DXCM. UBS Group lifted their price target on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Royal Bank of Canada initiated coverage on shares of DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target for the company. Raymond James raised their price objective on shares of DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a research note on Tuesday, January 23rd. StockNews.com raised shares of DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Finally, Citigroup raised their price objective on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $141.40.

DexCom Stock Performance

Shares of DexCom stock opened at $134.30 on Friday. The firm’s fifty day simple moving average is $129.35 and its 200-day simple moving average is $116.41. The stock has a market capitalization of $51.78 billion, a price-to-earnings ratio of 102.52, a PEG ratio of 2.30 and a beta of 1.20. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.07. The company had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.02 billion. DexCom had a net margin of 14.95% and a return on equity of 28.31%. DexCom’s revenue was up 26.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.34 EPS. As a group, equities analysts forecast that DexCom, Inc. will post 1.76 earnings per share for the current year.

Insider Transactions at DexCom

In other news, EVP Matthew Vincent Dolan sold 1,990 shares of the company’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $137.81, for a total transaction of $274,241.90. Following the transaction, the executive vice president now directly owns 42,377 shares of the company’s stock, valued at approximately $5,839,974.37. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, EVP Matthew Vincent Dolan sold 1,990 shares of the business’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the sale, the executive vice president now directly owns 42,377 shares in the company, valued at approximately $5,839,974.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Kevin R. Sayer sold 81,007 shares of the business’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the completion of the sale, the chief executive officer now owns 333,526 shares in the company, valued at $44,479,027.36. The disclosure for this sale can be found here. Insiders have sold a total of 189,375 shares of company stock valued at $25,530,859 in the last ninety days. 0.41% of the stock is currently owned by company insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.